ProStrakan Group Launching SANCUSO (Granisetron Transdermal System) in European Union With 3M Drug Delivery Systems as Manufacturer

ST. PAUL, Minn.--(BUSINESS WIRE)--The European Medicines Agency (EMA) has granted approval for ProStrakan Group plc to market SANCUSO® (Granisetron Transdermal System) in the European Union (EU), with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan begins marketing the product this month in the United Kingdom, Germany and the Netherlands. Additional European countries are expected to be added in 2014. Initially introduced in the United States in 2008, SANCUSO is the first and only treatment for chemotherapy-induced nausea and vomiting that does not require pills or intravenous (IV) administration. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting. This simple-to-use treatment has been proven effective in patients at risk for chemotherapy-induced nausea and vomiting.

Help employers find you! Check out all the jobs and post your resume.